Nuvilex Funding Has Investors Preparing for Milestone Announcements in Late-Phase Clinical Trials: investors who have patiently waited for the R&D biotech to reach a point where late-phase clinical trials were a reality, are probably relishing these truly exciting times after a Chicago-based institutional investor committed to fund $27 million dollars toward the companys clinical trials in advanced inoperable pancreatic cancer. Leading up to the aforementioned clinical trials, investors can expect to see a list of milestone developments unfold, and for those who consider themselves biotech junkies, they know this is when the fun begins. Source: marketwired/press-release/nuvilex-funding-has-investors-preparing-milestone-announcements-late-phase-clinical-otcqb-nvlx-1884541.htm
Posted on: Tue, 04 Mar 2014 13:38:28 +0000
Trending Topics
Recently Viewed Topics
© 2015